FIELD: biotechnology.
SUBSTANCE: described is a recombinant adeno-associated virus (AAV) vector comprising (a) variant AAV2 capsid protein, wherein the variant AAV2 capsid protein comprises at least four amino acid substitutions compared to the non-mutant type AAV2 capsid protein; where at least four amino acid substitutions are present in following positions in AAV2 sequence of capsid protein: 457, 492, 499 and 533; and (b) a heterologous nucleic acid containing a nucleotide sequence encoding a gene product.
EFFECT: invention can be used for treating neurological and eye diseases, as well as liver.
17 cl, 39 dwg, 1 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| VIRIONS OF AN ADENO-ASSOCIATED VIRUS WITH A VARIANT CAPSID AND METHODS FOR USING THEM | 2017 |
|
RU2742724C1 |
| MODIFIED FREEDREICH ATAXY GENES AND VECTORS FOR GENE THERAPY | 2016 |
|
RU2743792C2 |
| VIRIONS OF ADENO-ASSOCIATED VIRUS WITH OPTIONAL CAPSID AND METHODS OF THEIR USE | 2012 |
|
RU2611202C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| COMPOSITIONS, METHODS AND APPLICATIONS OF GENE TRANSFER FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2805606C2 |
| METHODS FOR ENHANCING BIOLOGICAL ACTIVITY OF RECOMBINANT ADENO ASSOCIATED VIRUS PRODUCED BY BACULOVIRUS SYSTEM | 2017 |
|
RU2762948C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2746991C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
| VERSIONS BASED ON ADENO-ASSOCIATED VIRUS, COMPOSITIONS AND METHODS FOR PULMONARY DELIVERY | 2021 |
|
RU2829874C1 |
| RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND WAYS OF THEIR USE FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS | 2018 |
|
RU2809246C2 |
